Delaying Lymph Node Biopsy After Melanoma Diagnosis Does Not Affect Survival Rates

A lymph node biopsy occurring more than 30 days after diagnosis is unlikely to have an adverse effect on the patients overall prognosis Postponing lymph node biopsy more than 30 days after melanoma diagnosis doesn8217t adversely impact long-term clinical [...]

New Study Suggests Most Cancers are Unavoidable Irrespective of Life Style

Two thirds of cancers are unavoidable even if you live a healthy life according to a study published by doctors from John Hopkins The research published in the journal Science indicates that the majority ofcancer-causing mutations are due to DNA copying e [...]

FDA Approves Nerlynx for Treatment of Early Stage HER2-Positive Breast Cancer

The US Food and Drug Administration approved Nerlynx eratinib for the extended adjuvant treatment of adult patients with early stage HER2-overexpressedamplified breast cancer to follow adjuvant trastuzumab-based therapy Approval was based on the ExteNET t [...]

Opdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma

A clinical trial evaluating Opdivo nivolumabversusYervoyipilimumab in patients with stage IIIbc or stage IV melanoma who are at high risk of recurrence following complete surgical resection has demonstrated a superior recurrence-free survivalin patients r [...]

Personalized Precision Medicine Treatment of Colon Cancer: What Every Patient Should Know

The purpose of precision cancer medicineis not to categorize or classify cancers solely by site of origin but to define the genomic alterations in the cancers DNA that are driving that specific cancer Precision cancer medicine utilizes molecular diagnosti [...]

Four-Year Follow-up with Empliciti Plus Revlimid in Patients with Advanced Multiple Myeloma Shows Long-term Beneift

Four-year follow-up data from the Phase 3 ELOQUENT-2 clinical trial in which Empliciti elotuzumab plus Revlimid lenalidomide continued to demonstrate effectiveness in patients with relapsedrefractory multiple myeloma compared to patients treated with Revl [...]

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL

Recommendation based on review of CTL019 rr B-cell ALL development program including the pivotal Phase II global ELIANA trial A Biologics License Application BLA for this indication is under FDA priority review if approved CTL019 could become first CAR-T [...]

Is Lynparza a Precision Cancer Medicine for Prostate Cancer?

Scientists have developed a new three-in-one blood test that has the potential to turn Lynparza olaparib into a precision medicine for prostate cancer Lynparza is a PARP inhibitor a newer precision cancer medicine that blocks enzymes involved in repairing [...]

Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer Promising

ARMO BioSciences Inc a late-stage immuno-oncology company announced clinical data on its lead investigational immuno-oncology drug AM0010 pegilodecakin PEGylatedInterleukin-10 at the ESMO 19thWorld Congress on Gastrointestinal Cancer taking place June28 t [...]

First-Line Immunotherapy Treatment Can Improve Survival for Subset of Lung Cancer Patients

Findings from a phase III clinical trial for advanced lung cancer patients could help oncologists better predict which patients are likely to receive the most benefit from immunotherapy as a first-line treatment based on the unique molecular characteristi [...]